Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Aug 10, 2026
Revenue (TTM)
$329.43B
+2.1% YoY
Gross margin
82.0%
EPS (latest q)
$0.96
vs $0.82 est · beat
52-wk position
46.0%
-23.6% vs 52w high · -4.5% 1mo
Price (last ~year)
Novo Nordisk (NVO) reports high profitability with a 42.5% operating margin and 35.3% profit margin, despite a 20.6% year-over-year decline in earnings and 2.1% revenue growth. The company holds $44.48 billion in cash against $140.13 billion in total debt, resulting in a 0.8x debt-to-EBITDA ratio. Shares recently closed at $47.26, following a 17.07% earnings beat in the quarter ending June 30, 2026, as the firm navigates competitive pressures in the weight-loss drug market.
Valuation
- Market cap
- $208.92B
- P/E
- 11.67
- PEG
- 3.198
- P/B
- 6.11
- P/S
- 0.634
- EV/EBITDA
- 8.25
- Beta
- 0.349
- Analyst target
- $47.32
Quality & returns
- Gross margin
- 82.0%
- Operating margin
- 42.5%
- Profit margin
- 35.3%
- ROE
- 59.8%
- ROA
- 18.7%
Price movement
- Last
- $47.26
- 1-month
- -4.5%
- 3-month
- +0.6%
- RSI (14)
- 42
- vs SMA200
- +3.2%
- 52-wk position
- 46.0% -23.6% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $78.49B | $27.06B | $20.99B | $38.68B |
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
Recent news
- Neutral Novo Nordisk makes Omnicom agency of record for US media buying · 2026-08-08
- Neutral Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem · 2026-08-07
- Somewhat-Bullish ‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth · 2026-08-07
- Neutral Novo Nordisk Awards U.S. Media Account to Omnicom 08/07/2026 · 2026-08-07
- Bullish Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market · 2026-08-06
- Somewhat-Bullish Novo Nordisk: what the Danish pharma giant does and makes · 2026-08-06
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)